Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided clopidogrel monotherapy (POPular GUILTY)
2022-003061-38Phase 4Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of clopidogrel in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) and coronary arteriosclerosis, sponsored by St. Antonius Ziekenhuis. Primary endpoint: Primary ischemic composite endpoint at 6 months. Started Mar 2023; status: active.
02
Drugs
clopidogrel
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2022-003061-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003061-38.